56 related articles for article (PubMed ID: 12413636)
1. Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study.
Millgate E; Kravariti E; Egerton A; Howes OD; Murray RM; Kassoumeri L; Donocik J; Lewis S; Drake R; Lawrie S; Murphy A; Collier T; Lees J; Stockton-Powdrell C; Walters J; Deakin B; MacCabe J
BMJ Open; 2021 Nov; 11(11):e054160. PubMed ID: 34824121
[TBL] [Abstract][Full Text] [Related]
2. Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study.
Chen PY; Chiu CC; Chang CK; Lu ML; Huang CY; Chen CH; Huang MC
J Psychopharmacol; 2024 Mar; 38(3):258-267. PubMed ID: 38279671
[TBL] [Abstract][Full Text] [Related]
3. Improving outcome of treatment-resistant schizophrenia: effects of cognitive remediation therapy.
Martini F; Spangaro M; Bechi M; Agostoni G; Buonocore M; Sapienza J; Nocera D; Ave C; Cocchi F; Cavallaro R; Bosia M
Eur Arch Psychiatry Clin Neurosci; 2023 Dec; ():. PubMed ID: 38114732
[TBL] [Abstract][Full Text] [Related]
4. Cognition, schizophrenia, and the atypical antipsychotic drugs.
Meltzer HY; Park S; Kessler R
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13591-3. PubMed ID: 10570115
[No Abstract] [Full Text] [Related]
5. A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia.
Sumiyoshi T; Jayathilake K; Meltzer HY
Schizophr Res; 2003 Jul; 62(1-2):65-72. PubMed ID: 12765745
[TBL] [Abstract][Full Text] [Related]
6. Augmentation therapy with serotonin
Yamada R; Wada A; Stickley A; Yokoi Y; Sumiyoshi T
Schizophr Res Cogn; 2023 Dec; 34():100290. PubMed ID: 37732133
[TBL] [Abstract][Full Text] [Related]
7. Effect of 5-HT1A Receptor Partial Agonists of the Azapirone Class as an Add-On Therapy on Psychopathology and Cognition in Schizophrenia: A Systematic Review and Meta-Analysis.
Yamada R; Wada A; Stickley A; Yokoi Y; Sumiyoshi T
Int J Neuropsychopharmacol; 2023 Apr; 26(4):249-258. PubMed ID: 36721972
[TBL] [Abstract][Full Text] [Related]
8. A knowledge graph of clinical trials ([Formula: see text]).
Chen Z; Peng B; Ioannidis VN; Li M; Karypis G; Ning X
Sci Rep; 2022 Mar; 12(1):4724. PubMed ID: 35304504
[TBL] [Abstract][Full Text] [Related]
9. The neural underpinnings of cognitive flexibility and their disruption in psychotic illness.
Waltz JA
Neuroscience; 2017 Mar; 345():203-217. PubMed ID: 27282085
[TBL] [Abstract][Full Text] [Related]
10. Mismatch negativity and p3a/reorienting complex in subjects with schizophrenia or at-risk mental state.
Higuchi Y; Seo T; Miyanishi T; Kawasaki Y; Suzuki M; Sumiyoshi T
Front Behav Neurosci; 2014; 8():172. PubMed ID: 24860454
[TBL] [Abstract][Full Text] [Related]
11. Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
Higuchi Y; Sumiyoshi T; Seo T; Miyanishi T; Kawasaki Y; Suzuki M
PLoS One; 2013; 8(1):e54080. PubMed ID: 23349791
[TBL] [Abstract][Full Text] [Related]
12. The Wisconsin Card Sorting impairment in schizophrenia is evident in the first four trials.
Prentice KJ; Gold JM; Buchanan RW
Schizophr Res; 2008 Nov; 106(1):81-7. PubMed ID: 17933496
[TBL] [Abstract][Full Text] [Related]
13. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
Kanes SJ; Tokarczyk J; Siegel SJ; Bilker W; Abel T; Kelly MP
Neuroscience; 2007 Jan; 144(1):239-46. PubMed ID: 17081698
[TBL] [Abstract][Full Text] [Related]
14. Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.
Bastianetto S; Danik M; Mennicken F; Williams S; Quirion R
BMC Neurosci; 2006 Mar; 7():28. PubMed ID: 16573831
[TBL] [Abstract][Full Text] [Related]
15. Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.
Sumiyoshi T; Roy A; Kim CH; Jayathilake K; Lee MA; Sumiyoshi C; Meltzer HY
Psychopharmacology (Berl); 2004 Dec; 177(1-2):79-83. PubMed ID: 15179543
[TBL] [Abstract][Full Text] [Related]
16. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia.
Sumiyoshi T; Jayathilake K; Meltzer HY
Schizophr Res; 2003 Jan; 59(1):7-16. PubMed ID: 12413636
[TBL] [Abstract][Full Text] [Related]
17. Melperone in the treatment of neuroleptic-resistant schizophrenia.
Meltzer HY; Sumiyoshi T; Jayathilake K
Psychiatry Res; 2001 Dec; 105(3):201-9. PubMed ID: 11814539
[TBL] [Abstract][Full Text] [Related]
18. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics.
Bobo WV; Jayathilake K; Lee MA; Meltzer HY
Psychiatry Res; 2010 Apr; 176(2-3):114-9. PubMed ID: 20199813
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
